Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Table. 1.

Patients’ Baseline Characteristics

Clinical characteristics Lactulose (n = 69) Combination (n = 68) S. boulardii (n = 50) P-value
Male 33 (47.8) 24 (35.3) 29 (58.0) 0.047a
Female 36 (52.2) 44 (64.7) 21 (42.0)
Age (mo) 42.3 ± 23.7 44.4 ± 23.6 38.6 ± 23.7 0.176
Disease duration (mo) 11.4 ± 11.3 7.6 ± 9.4 9.1 ± 11.2 0.109
Previous use of laxatives 9 (13.2) 17 (25.0) 7 (14.0) 0.178
Previous use of probiotics 27 (39.1) 28 (41.2) 21 (42.0) 0.970
Stool frequency/week 2.7 ± 1.8 2.9 ± 2.7 2.7 ± 2.2 0.883
Incontinency/week 1.2 ± 6.0 0.9 ± 3.0 3.0 ± 8.7 0.153
Stool consistency 1.7 ± 0.7 1.6 ± 0.8 1.9 ± 0.8 0.055
Painful defecation 66 (95.7) 63 (92.6) 49 (98.0) 0.396
Painful defecation/week 2.6 ± 1.8 2.3 ± 2.6 2.1 ± 1.3 0.484

aGender differences was observed between combination therapy group and S. boulardii monotherapy group.

S. boulardii, Saccharomyces boulardii.

Values are shown as n (%) or mean ± SD.

J Neurogastroenterol Motil 2022;28:454~462 https://doi.org/10.5056/jnm21130
© J Neurogastroenterol Motil